Stavrinides, V;
Dalgleish, A;
Copier, JP;
Moore, CM;
(2020)
Mycobacterial immunotherapy for prostate cancer: where can we go from here?
Nature Reviews Urology
, 17
pp. 189-190.
10.1038/s41585-020-0283-2.
Preview |
Text
Stavrinides_Mycobacterial immunotherapy for prostate cancer_AAM.pdf - Accepted Version Download (118kB) | Preview |
Abstract
The effects of mycobacteria in prostate cancer have not been fully elucidated. Results of early studies indicated that mycobacterial immunotherapy conferred a survival benefit in patients with advanced prostate cancer, and recent evidence supports the safety and efficacy of new mycobacterial agents in many malignancies; thus, modern, carefully designed, randomized controlled trials of mycobacterial immunotherapy for prostate cancer could be warranted.
Archive Staff Only
View Item |